# MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors

> **NCT00003028** · PHASE1 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 5 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** sabarubicin

## Key facts

- **NCT ID:** NCT00003028
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2012-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003028, "MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*